

Magnox announces new Chief Operating Officer

News story

Magnox has today announced the appointment of Paul Winkle as its new Chief Operating Officer (COO).



Paul Winkle takes up the role of Chief Operating Officer at Magnox

Most recently Paul held the role of Director on the Conventional Island Programme at Hinkley Point C and previously was Safety, Security and Assurance Director at EDF Energy Generation.

Paul will take up his role at Magnox on 1 May 2020.

Gwen Parry-Jones, Chief Executive Officer, said:

I am delighted to be welcoming Paul to the Magnox team. He has a wealth of experience in the nuclear sector, having joined the nuclear industry as a Senior Engineer more than 20 years ago.

Previously EDF Energy's Scottish Business Director based at Torness in Scotland, Paul has a proven track record of leadership and inspiring excellent results.

Published 29 April 2020

Transport update: project application extensions

- Only go outside for food, health reasons or work (but only if you cannot work from home)
- If you go out, stay 2 metres (6ft) away from other people at all times
- Wash your hands as soon as you get home

Do not meet others, even friends or family.

You can spread the virus even if you don't have symptoms.

Further expansion of prison estate to protect NHS

Press release

A former Secure Training Centre will receive its first adult prisoners today as part of further work to temporarily expand the prison estate to protect the public and NHS during the Coronavirus pandemic.



- Recently closed youth custody site in Kent reopened to hold up to 70 adult prisoners
- Over 300 temporary cells now delivered to nine prisons
- Extra capacity is reducing risk of outbreak in prisons, helping to protect local hospitals

This follows the installation of the first of 500 temporary, single occupancy cells which began three weeks ago. Over 300 have now been delivered to nine prisons.

Across the estate, prisons are moving towards single-cell accommodation, as much as possible, to limit the spread of infection and the number of deaths. The strong measures the Prison Service is taking – creating extra cells, limiting prisoner movement, releasing some prisoners early, isolating those with symptoms and quarantining new arrivals – are successfully limiting the transmission of the virus.

The latest modelling by Public Health England and HM Prison and Probation Service predicts a drastic reduction in the spread rates of the infection, with each case being passed on to less than one person – meaning lives should be saved and the NHS is being protected from the impact of widespread local outbreaks.

The former Medway Secure Training Centre, which closed in March, will be temporarily reopened as an annex to nearby HMP Rochester, housing up to 70 category D adult prisoners. It will be staffed by existing prison staff from local prisons in Kent.

Temporary cells have now been installed to serve HMPs Highpoint, Hollesley Bay and North Sea Camp. Installation continues at HMPs Askham Grange, Coldingley, Hatfield, Lindholme, Littlehey, Moorland and Wymott with plans to deliver to further prisons across the estate as required.

Published 29 April 2020

[Suffragan See of Lewes: 29 April 2020](#)

Press release

Queen approves nomination of the Reverend Prebendary William Peter Guy Hazlewood to the Suffragan See of Lewes.



The Queen has approved the nomination of the Reverend Prebendary William Peter Guy Hazlewood, Vicar of the United Benefice of Dartmouth and Dittisham

and Honorary Canon at Exeter Cathedral, in the Diocese of Exeter, to the Suffragan See of Lewes, in the Diocese of Chichester, in succession to the Right Reverend Richard Jackson following his translation to the See of Hereford.

Published 29 April 2020

[COVID-19 treatments could be fast-tracked through new national clinical trial initiative](#)

- rapidly scaled-up national initiative will mean clinical trials could start in weeks rather than months
- 6 drugs entering clinical trials as part of national effort made possible by government, academia and industry working together
- this will give an early indication of whether these drugs could save lives and improve the outcomes of the most vulnerable patients with COVID-19

Thousands of patients could benefit from potential treatments for COVID-19 that will be fast-tracked through a new national clinical trial, the Health and Care Secretary has today announced.

This platform will accelerate the development of new drugs for patients hospitalised with COVID-19, reducing the time taken to set up clinical studies for new therapies from months to just weeks and helping to ease pressure on the NHS and ultimately save lives.

6 potential drugs will initially enter the programme, with the first of these beginning phase 2 studies – the stage of a clinical trial focused on the testing of a drug on patients to assess how effective it is and side effects – across the UK imminently.

Announcing the news at today's press conference, Health and Social Care Secretary Matt Hancock said:

“Currently no drugs in the world have been clinically proven to treat COVID-19. But our Therapeutics Taskforce has identified a number of promising candidates. Currently, 6 different treatments have been entered into national

clinical trials and the first is ready to enter the next stage: a new early phase clinical trial platform that we are launching today.

This is a national effort made possible by government, academia and industry working together.”

Funded by the Department of Health and Social Care (DHSC) and the UK Research and Innovation (UKRI), this collaborative programme – known as the ACCORD (Accelerating COVID-19 Research & Development platform) – aims to get an early indication of drug treatments’ effectiveness in treating coronavirus and if positive results are seen, these drugs will advance rapidly into the large-scale trials currently in progress across the country.

ACCORD brings together a single, UK-wide clinical trial platform provided by the clinical research company IQVIA and the UK’s leading research expertise through the National Institute for Health Research (NIHR), to rapidly test potential drugs through early stage clinical trials and feed them into the UK’s large-scale COVID-19 studies such as the [RECOVERY trial](#), currently the world’s largest randomised controlled clinical trial for COVID-19 treatment. It is reducing the time taken to set up clinical studies from months to just weeks.

ACCORD is part of a co-ordinated therapeutic development pathway that the government has put in place, overseen by the Department for Business, Energy and Industrial Strategy and delivered by the UKRI, as part of the overall Therapeutics Taskforce.

Business Secretary Alok Sharma said:

“The UK is home to world-class scientists and researchers who are united in their aim to defeat coronavirus.

“Through ACCORD, we are bringing together the government, industry and research organisations to speed up the development of effective new coronavirus treatments, helping to save thousands of people’s lives and benefiting our NHS.”

Further potential treatments will be rapidly fed into ACCORD as the programme rolls out over the next few weeks.

UK Research and Innovation Chief Executive, Professor Sir Mark Walport said:

“This initiative will rapidly test the most promising drugs in the fight against COVID-19. Bringing together expertise from across the UK’s world-class research and innovation sectors – from clinical researchers through to the pharmaceutical industry – this national platform will rapidly prioritise and deliver the best potential drugs into clinical trials to discover if they can help people with COVID-19.”

ACCORD has been made possible by partnership working between the Government Scientific Office, the NIHR’s Biomedical Research Centres and Clinical Research Facilities, and expert centres in Northern Ireland, Scotland and Wales, clinical research company IQVIA and biopharmaceutical company

AstraZeneca.

Professor Tom Wilkinson, ACCORD clinical academic lead based at the NIHR Southampton Biomedical Research Centre, said:

“There has been a tremendous effort to pull this initiative together so rapidly. ACCORD is a national effort and will be key to developing effective new treatments which are needed so desperately.”

“The ACCORD platform will be able to rapidly test potential new treatments, advancing the most promising through phase 2 clinical trials into the NHS. This unique national platform for developing new COVID-19 drug candidates will access the world-class expertise and resources of the NIHR Respiratory Translational Research Collaboration and allied centres nationwide.”

Through the Therapeutic Taskforce, the life science sector can suggest potential drugs or molecules that could be tested through the ACCORD platform. Data will be open source and freely available to enable global knowledge sharing and collaboration.

Dr Jonathan Sheffield, NIHR COVID-19 Research Operations Director said:

“ACCORD will transform the way in which the UK’s research community finds treatments for global healthcare challenges such as COVID-19. ACCORD is an exemplary case of government, industry and research organisations working together with urgency, to the benefit of patients and the NHS.”

“The NIHR’s experimental medicine infrastructure of people, facilities and technology is well-placed to fast-track research into COVID-19 treatments.”

In addition to the first drugs being tested, the Therapeutics Task Force continues to identify potential early stage drugs to be trialled through the ACCORD platform.

IQVIA is providing a national, single platform to ACCORD and will deliver the trials via NIHR’s world-class network of investigators and research facilities, and partners sites in Northern Ireland, Scotland and Wales. AstraZeneca will work with the pharmaceutical industry to scope and support rapid upscaling of development and trials.

Tim Sheppard IQVIA UK GM and SVP Northern Europe said:

“COVID-19 is the greatest public health challenge that has faced the world in a generation. Hyper-accelerating clinical trials of medicines in discovery pipelines could be instrumental in saving many lives in the UK and beyond.”

“IQVIA is proud to be able to mobilise our platform and use our vast network of clinical trial infrastructure, research expertise and data analytics to work with the ACCORD partners to develop treatments that can change the course of this pandemic.”

The first wave of new and existing medicines to be tested through the ACCORD-2 platform are:

For further info on the BerGenBio compound, please contact Richard Godfrey, CEO of BerGenBio, at media@bergenbio.com.